The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression

Journal of Neuro-Oncology

Volumn 87, Issue 2, 2008, Pages 165-171

  Fisher, Michael J ^a,b   Basu, Sandip ^c   Dombi, Eva ^d   Yu, Jian Q ^c   Widemann, Brigitte C ^d   Pollock, Avrum N ^a,b   Cnaan, Avital ^a,b   Zhuang, Hongming ^c   Phillips, Peter C ^a,b   Alavi, Abass ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

FDG; Fluorodeoxyglucose; MRI; Neurofibroma; Neurofibromatosis type 1; NF1; PET; Plexiform; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER LOCALIZATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; MALE; METABOLIC RATE; NEUROFIBROMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUANTITATIVE ANALYSIS; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; CHILD; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEUROFIBROMA, PLEXIFORM; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 41549104318     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9501-5     Document Type: Article

References (33)

1. Barker D, Wright E, Nguyen K et al (1987) Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 236:1100-1102
2. Viskochil D, Buchberg AM, Xu G et al (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192
3. Wallace MR, Marchuk DA, Andersen LB et al (1990) Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science 249:181-186
4. Korf BR (1999) Plexiform neurofibromas. Am J Med Genet 89:31-37
5. Dombi E, Solomon J, Gillespie AJ et al (2007) NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight. Neurology 68:643-647
6. Hoh CK, Hawkins RA, Glaspy JA et al (1993) Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy- D -glucose. J Comput Assist Tomogr 17:582-589
7. Moog F, Bangerter M, Diederichs CG et al (1997) Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro- D -glucose (FDG) PET in nodal staging. Radiology 203:795-800
8. Wong TZ, van der Westhuizen GJ, Coleman RE (2002) Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12:615-626
9. Adler LP, Blair HF, Makley JT et al (1991) Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 32:1508-1512
10. Ferner RE, Lucas JD, O'Doherty MJ et al (2000) Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 68:353-357
11. Kern KA, Brunetti A, Norton JA et al (1988) Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 29:181-186
12. Lodge MA, Lucas JD, Marsden PK et al (1999) A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26:22-30
13. Molloy P, Defeo R, Hunter J et al (1999) Excellent correlation of FDG-PET imaging with clinical outcome in patients with neurofibromatosis type 1 and low grade astrocytomas. J Nucl Med 40:129P
14. Schulte M, Brecht-Krauss D, Heymer B et al (1999) Fluorodeoxyglucose positron emission tomography of soft tissue tumours: Is a non-invasive determination of biological activity possible? Eur J Nucl Med 26:599-605
15. Solomon J, Warren K, Dombi E et al (2004) Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph 28:257-265
16. Basu S, Zaidi H, Houseni M et al (2007) Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: Implications for normal variation, aging and diseased states. Semin Nucl Med 37:223-239
17. Aoki J, Watanabe H, Shinozaki T et al (2001) FDG PET of primary benign and malignant bone tumors: Standardized uptake value in 52 lesions. Radiology 219:774-777
18. Feldman F, van Heertum R, Manos C (2003) 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 32:201-208
19. Ruggieri M (1999) The different forms of neurofibromatosis. Childs Nerv Syst 15:295-308
20. Huson SM, Harper PS, Compston DA (1988) Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111(Pt 6):1355-1381
21. Tonsgard JH, Kwak SM, Short MP et al (1998) CT imaging in adults with neurofibromatosis-1: Frequent asymptomatic plexiform lesions. Neurology 50:1755-1760
22. Waggoner DJ, Towbin J, Gottesman G et al (2000) Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet 92:132-135
23. Evans DG, Baser ME, McGaughran J et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311-314
24. Needle MN, Cnaan A, Dattilo J et al (1997) Prognostic signs in the surgical management of plexiform neurofibroma: The children's hospital of Philadelphia experience, 1974-1994. J Pediatr 131:678-682
25. Basu S, Nair N (2006) Potential clinical role of FDG-PET in detecting sarcomatous transformation in von Recklinghausen's disease: A case study and review of the literature. J Neurooncol 80:91-95
26. Chander S, Westphal SM, Zak IT et al (2004) Retroperitoneal malignant peripheral nerve sheath tumor: Evaluation with serial FDG-PET. Clin Nucl Med 29:415-418
27. Otsuka H, Graham MM, Kubo A et al (2005) FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: A case report. Ann Nucl Med 19:55-58
28. Solomon SB, Semih Dogan A, Nicol TL et al (2001) Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis. Clin Nucl Med 26:525-528
29. Brenner W, Friedrich RE, Gawad KA et al (2006) Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 33:428-432
30. Cardona S, Schwarzbach M, Hinz U et al (2003) Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29:536-541
31. Avril NE, Weber WA (2005) Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 43:189-204
32. Kostakoglu L, Goldsmith SJ (2003) 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 44:224-239
33. Westerterp M, van Westreenen HL, Reitsma JB et al (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 236:841-851